Affiliation:
1. School of Pharmaceutical Sciences São Paulo State University (UNESP) Araraquara SP 14800‐903 Brazil
2. i3S – Instituto de Investigação e Inovação em Saúde University of Porto Porto 4200‐135 Portugal
3. INEB – Instituto de Engenharia Biomédica University of Porto Porto 4200‐135 Portugal
4. CESPU IUCS Gandra 4585‐116 Portugal
Abstract
AbstractThe encapsulation of bevacizumab (BVZ), angiogenesis inhibitor antibody, into nanocarriers is explored aiming at enhancing its efficacy in colorectal cancer (CRC) treatment while eliminating potential side effects. Still, the translation of such nanomedicines into clinics is not straightforward owing to their preclinical screening in simplistic models, that do not mimic the complexity and heterogeneity of the CRC microenvironment. Herein, the development of a multicellular spheroid of CRC as an advanced preclinical model of CRC capable of screening the antiangiogenic potential of novel nanomedicines is proposed. For that, a quadruple co‐culture is established through the combination of HCT116 cells, human pulmonary microvascular endothelial cell (HPMEC), fibroblasts, and macrophages. It is demonstrated that the developed model displays intrinsic CRC features, such as the organization of cells, expression of tumor microenvironment, extracellular matrix, and the formation of a necrotic core. Moreover, the model is shown to be composed mostly of HCT116 (93%), followed by hypoxia‐inducible factor (3%), HPMEC (3%), and macrophages (1%). Gellan gum/chitosan nanoparticles encapsulating BVZ exhibit superior antiangiogenic properties when compared to free BVZ. Overall, the developed nanoparticles can further be explored as a promising approach in CRC treatment.
Subject
Pharmacology (medical),Biochemistry (medical),Genetics (clinical),Pharmaceutical Science,Pharmacology,Medicine (miscellaneous)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献